Labcorp Holdings Inc.

$333.80

+0.34%

2026-09-01 09:37:03 EDT+$1.14

Healthcare

Medical - Diagnostics & Research

NYSE

Active Trading

Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed ...

Price Action of LH

$333.80

+0.34%+$1.14

High—

Low—

52W High-2.1%

Rel. vol—

Interval

Range6.4h

Volume—SMA5SMA10

—

Company Overview of LH

Labcorp Holdings Inc. (NYSE: LH) is a global life sciences and healthcare company headquartered in Burlington, North Carolina. Founded in 1978 as National Health Laboratories and later renamed after a 1995 merger, Labcorp provides comprehensive laboratory services including diagnostics, drug development, and clinical trials. With over 71,000 employees, the company ...Labcorp Holdings Inc. (NYSE: LH) is a global life sciences and healthcare company headquartered in Burlington, North Carolina. Founded in 1978 as National Health Laboratories and later renamed after a 1995 merger, Labcorp provides comprehensive laboratory services including diagnostics, drug development, and clinical trials. With over 71,000 employees, the company operates in more than 100 countries, serving a diverse clientele. Its core business encompasses clinical laboratory testing, diagnostic services, and biopharmaceutical development support, generating annual revenue exceeding $14 billion. Labcorp emphasizes innovation, leveraging advanced diagnostic technologies and data analytics to improve patient outcomes. Key financial metrics show a market cap of approximately $26 billion, with consistent dividends and a focus on strong cash flow. The company is led by Adam H. Schechter as CEO since November 2019 and Chairman since May 2020. Labcorp is dedicated to its mission of 'Improving Health, Improving Lives,' and contributes significantly to medical research and public health. It also prioritizes diversity and sustainability, with a commitment to reducing its environmental impact. Overall, Labcorp is integral to modern healthcare, enabling precision medicine and enhancing human well-being globally.ExpandCollapse

Founded

1978

Employees

71000

CEO

Adam H. Schechter

Full Name

Labcorp Holdings Inc.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

ROE

11.57%

Market Cap

$27.37B

Current Ratio

1.80

WACC

7.52%

ROIC

7.64%

Contact Information

https://www.labcorp.com

336 229 1127

358 South Main Street, Burlington, NC 27215

Key Metrics of LH

Snapshot

Latest / TTM · 6 periods

Market Cap

$27.37B

ROCE

9.9%

EV / EBITDA

15.71x

+0.1% YoY

FCF Yield

4.2%

-1.5% YoY

Cash Conversion Cycle

59.3d

Current Ratio

1.80

Quick take

TTM —

Positive CCC

Financial Highlights of LH

Profitability trend

Latest / TTM · 6 periods

Gross Margin

27.8%

Net Margin

7.0%

P/E Ratio

27.24x

n/a

Debt / Equity

0.79

n/a

Current Ratio

1.80

Dividend Yield

0.9%

Understanding

TTM —

No major balance sheet stress in these headline ratios.

Calendar of LH

Upcoming

Sep 11, 2026In 7 days
Dividend payment
$2.88 per share
Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $4.65 · Revenue $3.76B · 10 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $4.45 · Revenue $3.72B · 9 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $18.35 · Revenue $14.75B · 10 analysts

Recent history

Aug 28, 2026
Ex-dividend date
$2.88 per share
Aug 5, 2026
Q2 FY2026 · Results reported
EPS $3.64 · Revenue $3.73B
View filing
May 4, 2026
Q1 FY2026 · Results reported
EPS $3.35 · Revenue $3.54B
View filing
Feb 24, 2026
FY2025 · Annual results
EPS $10.46 · Revenue $13.95B
View filing
Sep 30, 2025
Q3 FY2025 · Results reported
EPS $3.12 · Revenue $3.56B
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $2.84 · Revenue $3.53B

Financial Statements of LH

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$14.0B	+7.2%	+5.5%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$876.5M	+17.5%	+7.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+26.8%	-4.0%	+12.4%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	+10.9%	+30.1%	+10.6%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	+6.3%	+9.6%	+1.9%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$1.2B	+10.0%	+345.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	+8.6%	+2.6%	+322.2%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	83.6%	-7.5%	-5.2%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	1.42x	-1.3%	+4.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$18.4B	+0.1%	-2.9%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	10.46 vs 16.33	-36.0%	3.64 vs 4.65	-21.8%
Revenue Surprise	$14.0B vs $14.0B	-0.3%	$3.7B vs $3.8B	-0.7%

Insider Transactions of LH

Acquisitions (A)

Since Aug 3, 2026

Disposals (D)

Since Aug 3, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Sep 1, 2026	Oyegunwa Akinbolade	officer: EVP, CIO & CTO	Restricted Stock Unit	A	750	—
Sep 1, 2026	Meltzer Jonathan C	officer: EVP, COO	Restricted Stock Unit	A	900	—
Sep 1, 2026	Vaughn Bryan T	officer: EVP and President, Diagnostics	Restricted Stock Unit	A	1,500	—
Sep 1, 2026	Caveney Brian J	officer: EVP, Pres of BLS, CMO & CSO	Restricted Stock Unit	A	3,000	—
Aug 17, 2026	ANDERSON KERRII B	director	Common Stock	D	3,000	$318.02

Earnings Call Transcript of LH

1 transcript segments

Q2 2026

Unknown Speaker

Operator: Good day, and thank you for standing by. Welcome to the Q2 2026 Labcorp Holdings Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Dewey Steadman, Senior Vice President, Investor Relations. Please go ahead. Dewey Steadman: Good morning, and welcome to Labcorp's Second Quarter 2026 Financial Results Webcast. With me today are Adam Schechter, our Chairman and Chief Executive Officer; and Julia Wang, our Executive Vice President and Chief Financial Officer. This morning, in the Events section of the Labcorp Investor Relations website at ir.labcorp.com, we posted both our press release and a supplemental financial presentation with additional information on our business and operations. We will also post a replay of this webcast on the IR website for 1 year. On today's webcast, we will focus on our adjusted or non-GAAP results for the second quarter of 2026, our capital allocation strategy and our updated financial guidance for the full year 2026. Our GAAP results and a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures are available in today's earnings release and the supplemental financial presentation. Please see the Use of Adjusted Measures section in the supplemental presentation for more information regarding our use of non-GAAP financial measures. In today's remarks, the term organic growth excludes the impact from acquisitions, divestitures, and currency, as well as other strategic actions taken in the Early Development business. Our remarks will also include forward-looking statements, including, but not limited to, statements about our updated 2026 financial guidance and the assumptions underlying that guidance; the expected impact of various factors on our business, operating and financial results, cash flows and financial condition; global economic and market conditions; our future business strategies; the expected savings, benefits, and synergies from acquisitions, strategic actions, and partnerships; and our potential opportunities for future growth. Each of these forward-looking statements is subject to change based upon various factors, many of which are beyond our control. More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Forms 10-Q and in the company's other filings with the SEC. We have no obligation to provide any updates to these forward-looking statements, even if our expectations change. Now, I'll turn the call over to Labcorp's Chairman and CEO, Adam Schechter. Adam? Adam Schechter: Thank you, Dewey, and good morning, everyone. We appreciate you joining us today to review our second quarter 2026 results. Labcorp delivered another very strong quarter driven by solid revenue growth, margin expansion, and progress across our strategic priorities. Our Diagnostics and Biopharma …

Leadership Team of LH

12 executives

Name	Title	Compensation	Gender	Year Born	Status
Adam H. Schechter	President, Chief Executive Officer & Chairman	USD 4,184,868	Male	1965	Active
Julia Wang	Chief Financial Officer & Executive Vice President	USD 1,684,514	Female	1972	Active
Anita Z. Graham	Executive Vice President & Chief Human Resources Officer	USD 1,576,023	Female	1971	Active
Brian J. Caveney	EVice President, President of Early Development Research Laboratories and Chief Medical & Scientific Officer	USD 1,493,883	—	1974	Active
Megan D. Bailey	Executive VP and President of Central Laboratory Services & International Labcorp	USD 1,150,873	Female	1980	Active
Akinbolade Oyegunwa	Executive Vice President and Chief Information & Technology Officer	USD 876,616	Male	1983	Active
Dewey Steadman	Senior Vice President of Investor Relations	—	Male	—	Active
Kathryn Wright Kyle	Executive Vice President, Chief Legal Officer & Corporate Secretary	—	Female	1971	Active
Jonathan C. Meltzer	EVP & Chief Operations Officer	—	Male	—	Active
Peter J. Wilkinson	Senior Vice President & Chief Accounting Officer	—	Male	1971	Active
Christin O'Donnell	Vice President of Investor Relations	—	—	—	Active
Amy Summy	EVP, Chief Marketing Officer & Consumer Health Lead	—	Female	1966	Active

Recent News of LH

Zacks Investment Research8/7/2026Neutral

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

Zacks Investment Research8/4/2026Neutral

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PRNewsWire8/4/2026Neutral

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.

MarketBeat7/31/2026Neutral

Labcorp Q2 Earnings Call Highlights

Labcorp NYSE: LH reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance.

Seeking Alpha7/30/2026Neutral

Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript

Historical Employee Count of LH

Current

71,000

Change

+1.43%

Minimum

67,000

Maximum

80,000

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	71,000	10-K	Feb 24, 2026	View
Dec 31, 2024	70,000	10-K	Feb 25, 2025	View
Dec 31, 2023	67,000	10-K	Feb 26, 2024	View
Dec 31, 2022	80,000	10-K	Feb 28, 2023	View
Dec 31, 2021	75,500	10-K	Feb 25, 2022	View

Related stocksMedical - Diagnostics & Research

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Labcorp Holdings Inc.